NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells

Cell Reports

Volumn 9, Issue 1, 2014, Pages 90-103

  Wang, David J ^a,b   Ratnam, Nivedita M ^a   Byrd, John C ^b   Guttridge, Denis C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; PROTEIN BCL 2; PROTEIN BCL XL; RAS PROTEIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; LCP1 PROTEIN, MOUSE; PHOSPHOPROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; GENE MUTATION; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INNATE IMMUNITY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SENESCENCE; TUMOR SUPPRESSOR GENE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETICS; IMMUNOLOGY; PATHOLOGY; PRECANCER; RISK FACTOR; SCID MOUSE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADAPTIVE IMMUNITY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; IMMUNITY, INNATE; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; NF-KAPPA B; PHOSPHOPROTEINS; PRECANCEROUS CONDITIONS; RAS PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907974652     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.08.049     Document Type: Article

References (44)

1. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222:155-161.
2. Alpizar Y.A., Chain B., Collins M.K., Greenwood J., Katz D., Stauss H.J., Mitchison N.A. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol. Immunother. 2011, 60:1127-1135.
3. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
4. Campisi J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2013, 75:685-705.
5. Chan H., Bartos D.P., Owen-Schaub L.B. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol. Cell. Biol. 1999, 19:2098-2108.
6. Chaturvedi M.M., Sung B., Yadav V.R., Kannappan R., Aggarwal B.B. NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011, 30:1615-1630.
7. Collado M., Serrano M. Senescence in tumours: evidence from mice and humans. Nat. Rev. Cancer 2010, 10:51-57.
8. Dajee M., Lazarov M., Zhang J.Y., Cai T., Green C.L., Russell A.J., Marinkovich M.P., Tao S., Lin Q., Kubo Y., Khavari P.A. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003, 421:639-643.
9. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
10. Finco T.S., Westwick J.K., Norris J.L., Beg A.A., Der C.J., Baldwin A.S. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J.Biol. Chem. 1997, 272:24113-24116.
11. Gapuzan M.E., Schmah O., Pollock A.D., Hoffmann A., Gilmore T.D. Immortalized fibroblasts from NF-kappaB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras. Oncogene 2005, 24:6574-6583.
12. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
13. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
14. Hanson J.L., Hawke N.A., Kashatus D., Baldwin A.S. The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 2004, 64:7248-7255.
15. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
16. Hopewell E.L., Zhao W., Fulp W.J., Bronk C.C., Lopez A.S., Massengill M., Antonia S., Celis E., Haura E.B., Enkemann S.A., et al. Lung tumor NF-κB signaling promotes Tcell-mediated immune surveillance. J.Clin. Invest. 2013, 123:2509-2522.
17. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 2009, 1:a000141.
18. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
19. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 2002, 3:999-1005.
20. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
21. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
22. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
23. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
24. Mayo M.W., Wang C.Y., Cogswell P.C., Rogers-Graham K.S., Lowe S.W., Der C.J., Baldwin A.S. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997, 278:1812-1815.
25. Meylan E., Dooley A.L., Feldser D.M., Shen L., Turk E., Ouyang C., Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
26. Mueller M.M., Fusenig N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4:839-849.
27. Noon A.T., Shibata A., Rief N., Löbrich M., Stewart G.S., Jeggo P.A., Goodarzi A.A. 53BP1-dependent robust localized KAP-1 phosphorylation is essential for heterochromatic DNA double-strand break repair. Nat. Cell Biol. 2010, 12:177-184.
28. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 2003, 21:807-839.
29. Perkins N.D. NF-kappaB: tumor promoter or suppressor?. Trends Cell Biol. 2004, 14:64-69.
30. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
31. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998, 12:968-981.
32. Rovillain E., Mansfield L., Caetano C., Alvarez-Fernandez M., Caballero O.L., Medema R.H., Hummerich H., Jat P.S. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene 2011, 30:2356-2366.
33. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
34. Schwitalla S., Fingerle A.A., Cammareri P., Nebelsiek T., Göktuna S.I., Ziegler P.K., Canli O., Heijmans J., Huels D.J., Moreaux G., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38.
35. Seitz C.S., Lin Q., Deng H., Khavari P.A. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc. Natl. Acad. Sci. USA 1998, 95:2307-2312.
36. Shaked H., Hofseth L.J., Chumanevich A., Chumanevich A.A., Wang J., Wang Y., Taniguchi K., Guma M., Shenouda S., Clevers H., et al. Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc. Natl. Acad. Sci. USA 2012, 109:14007-14012.
37. Skalka A.M., Katz R.A. Retroviral DNA integration and the DNA damage response. Cell Death Differ. 2005, 12(Suppl 1):971-978.
38. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., Sonenshein G.E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J.Clin. Invest. 1997, 100:2952-2960.
39. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2010, 2:a000109.
40. Tergaonkar V., Pando M., Vafa O., Wahl G., Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002, 1:493-503.
41. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
42. Wang J., Jacob N.K., Ladner K.J., Beg A., Perko J.D., Tanner S.M., Liyanarachchi S., Fishel R., Guttridge D.C. RelA/p65 functions to maintain cellular senescence by regulating genomic stability and DNA repair. EMBO Rep. 2009, 10:1272-1278.
43. Zaynagetdinov R., Stathopoulos G.T., Sherrill T.P., Cheng D.S., McLoed A.G., Ausborn J.A., Polosukhin V.V., Connelly L., Zhou W., Fingleton B., et al. Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene 2012, 31:3164-3176.
44. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.